First results of the BIOCYCLE project will be presented during the ECCO’17 Congress in Barcelona on February 15th, 2017

First results of the BIOCYCLE project will be presented during the ECCO’17 Congress in Barcelona on February 15th, 2017

This project, funded by the European commission under the Horizon 2020 program, aims at exploring different aspects of the question of treatment de-escalation in moderate-severe Crohn’s disease (CD), first requiring a combination therapy with anti-TNF and antimetabolites to control the disease. The global aim of BIOCYCLE is to try and bring an integrated multidimensional and tailored response to this difficult question of treatment de-escalation in Crohn’s disease, also taking into account patients’ preferences and perspectives.

A digital oral presentation will summarize the first results of the healthcare providers’ survey, performed in United States (US) (through CCFA channels) and in Europe (through ECCO). Indeed, when patients with CD are in remission on combination therapy including an anti-TNF agent and an anti-metabolite, a frequent question is if it is appropriate to stop one of these medications. The aim of this survey was to capture and understand gastroenterologists’ perspectives (expectations, fears, priorities) on stopping therapy for patients with CD who are in remission, and to identify differences between European and US providers.

The SPARE clinical trial has also fully started and multiple centres are currently recruiting. Over 70 patients have been recruited so far in about 30 centres. Overall the recruitment process should be prolonged all over 2017 and 300 patients are expected to be recruited in 70 centres.

EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014) 

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials